Cyclosporine A and its non-immunosuppressive derivative NIM811 induce apoptosis of malignant melanoma cells in in vitro and in vivo studies

International Journal of Cancer

Volumn 117, Issue 1, 2005, Pages 59-67

  Ciechomska, Iwona ^a   Legat, Magdalena ^a   Golab, Jakub ^b   Wesolowska, Aleksandra ^a,b   Kurzaj, Zuzanna ^a   Mackiewicz, Andrzej ^c   Kaminska, Bozena ^a  

^a NENCKI INSTITUTE OF EXPERIMENTAL BIOLOGY   (Poland)

^b MEDICAL UNIVERSITY OF WARSAW   (Poland)

^c POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

Author keywords

Apoptosis; Caspase activation; Immunosuppressant; Malignant melanoma cells

Indexed keywords

CASPASE 3; CASPASE 7; CASPASE 9; CASPASE INHIBITOR; CYCLOSPORIN A; CYCLOSPORIN DERIVATIVE; DNA FRAGMENT; FAS ANTIGEN; FAS LIGAND; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NIM 811; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL CYCLE; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG BLOOD LEVEL; ENZYME IMMUNOASSAY; ENZYME INACTIVATION; FLOW CYTOMETRY; GEL ELECTROPHORESIS; HUMAN; HUMAN CELL; MELANOMA CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR VOLUME; WESTERN BLOTTING;

ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CASPASES; CELL SURVIVAL; CYCLOSPORINE; DNA, NEOPLASM; ENZYME ACTIVATION; G1 PHASE; HUMANS; MALE; MELANOMA, EXPERIMENTAL; MICE; POLY(ADP-RIBOSE) POLYMERASES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR CELLS, CULTURED;

EID: 24344467862     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.21153     Document Type: Article

References (38)

1. Clark WH, Elder DE, Guerry D, Epstein MN, Greene MH, Van Horn M. A study of tumor progression: the precursor lesions of superficial spreading and nodular melanoma. Hum Pathol 1984;15:1147-65.
2. Herlyn M, Thurin J, Balaban G, Bennicelli JL, Herlyn D, Elder DE, Bondi E, Guerry D, Nowell P, Clark WH, Koprowski H. Characteristics of cultured human melanocytes isolated from different stages of tumor progression. Cancer Res 1985;45:5670-6.
3. Serrone L, Hersey P. The chemoresistance of human malignant melanoma: an update. Melanoma Res 1999;9:51-8.
4. Helmbach H, Rossmann E, Kern MA, Schadendorf D. Drug-resistance in human melanoma. Int J Cancer 2001;93:617-22.
5. Kaufmann SH, Earnshaw WC. Induction of apoptosis by cancer chemotherapy. Exp Cell Res 2000;256:42-9.
6. Houahton JA. Apoptosis and drug response. Curr Opin Oncol 1999;11:475-81.
7. Wyllie AH. Glucocorticoid-induced thymocyte apoptosis is associated with endogenous endonuclease activation. Nature 1980;284:555-6.
8. Lazebnik YA, Cole S, Cooke CA, Nelson WG, Earnshaw WC. Nuclear events of apoptosis in vitro in cell-free mitotic extracts: a model system for analysis of the active phase of apoptosis. J Cell Biol 1993;123:7-22.
9. Kaufmann SH. Induction of endonucleolytic DNA cleavage in human acute myelogenous leukemia cells by etoposide, camptothecin, and other cytotoxic anticancer drugs: a cautionary note. Cancer Res 1989;49:5870-8.
10. Lazebnik YA, Kaufmann SH, Desnoyers S, Poirier GG, Earnshaw WC. Cleavage of poly(ADP-ribose) polymerase by a proteinase with properties like ICE. Nature 1994;371:346-7.
11. Lazebnik YA, Takahashi A, Moir RD, Goldman RD, Poirier GG, Kaufmann SH, Earnshaw WC. Studies of the lamin proteinase reveal multiple parallel biochemical pathways during apoptotic execution. Proc Natl Acad Sci USA 1995;92:9042-6.
12. Cohen GM. Caspases: the executioners of apoptosis. Biochem J 1997;326:1-16.
13. Kumar S. Mechanisms mediating caspase activation in cell death. Cell Death Differ 1999;6:1060-6.
14. Nicholson DW. Caspase structure, proteolytic substrates, and function during apoptotic cell death. Cell Death Differ 1999;6:1028-42.
15. Kolenko VM, Uzzo RG, Bukowski R, Finke JH. Caspase-dependent and -independent death pathways in cancer therapy. Apoptosis 2000;5:17-0.
16. Fulda S, Kufer MU, Meyer E, van Valen F, Dockhorn-Dworniczak B, Debatin KM. Sensitization for death receptor- or drug-induced apoptosis by re-expression of caspase-8 through demethylation or gene transfer. Oncogene 2001;20:5865-77.
17. Soengas MS, Capodieci P, Polsky D, Mora J, Esteller M, Opitz-Araya X, McCombie R, Herman JG, Gerald WL, Lazebnik YA, Cordon-Cardo C, Lowe SW. Inactivation of the apoptosis effector Apal-1 in malignant melanoma. Nature 2001;409:207-11.
18. Mosieniak G, Figiel I, Kaminska B. Cyclosporine A, an immunosuppressive drug, induces programmed cell death in rat C6 glioma cells by a mechanism that involves the AP-1 transcription factor. J Neurochem 1997;68:1142-9.
19. Mosieniak G, Pyrzynska B, Kaminska B. Nuclear factor of activated T cells (NFAT) as a new component of the signal transduction pathway in glioma cells. J Neurochem 1998;71:134-41.
20. Pyrzynska B, Lis A, Mosieniak G, Kaminska B. Cyclosporine A-sensitive signalling pathway involving calcineurin regulates survival of reactive astrocytes. Neurochem Int 2001;38:409-15.
21. Pyrzynska B, Serrano M, Martinez-A C, Kaminska B. Tumor suppressor p53 mediates apoptotic cell death triggered by cyclosporin. J Biol Chem 2002;277:14102-8.
22. Clipstone NA, Crabtree GR. Identification of calcineurin as a key signalling enzyme in T-lymphocyte activation. Nature 1992;357:695-7.
23. Shaw KT, Ho AM, Raghavan A, Kim J, Jain J, Park J, Sharma S, Rao A, Hogan PG. Immunosuppressive drugs prevent a rapid dephosphorylation of transcription factor NFAT1 in stimulated immune cells. Proc Natl Acad Sci USA 1995;92:11205-9.
24. Macian F, Lopez-Rodriguez C, Rao A. Partners in transcription: NFAT and AP-1. Oncogene 2001;20:2476-89.
25. Pyrzynska B, Mosieniak G, Kaminska B. Changes of the trans-activating potential of AP-1 transcription factor during cyclosporine A-induced apoptosis of glioma cells are mediated by phosphorylation and alterations of AP-1 composition. J Neurochem 2000;74:42-51.
26. Waldmeier PC, Feldtrauer J-J, Qian T, Lemasters JJ. Inhibition of the mitochondrial permeability transition by the nonimmunosuppressive cyclosporin derivative NIM811. Mol Pharmacol 2002;62:22-9.
27. Herlyn M. Human melanoma: development and progression. Cancer Metastasis Rev 1990;9:101-12.
28. Earnshaw WC, Martins LM, Kaufmann SH. Mammalian caspases: structure, activation, substrates, and functions during apoptosis. Annu Rev Biochem 1999;68:383-424.
29. Ciechomska I, Pyrzynska B, Kazmierczak P, Kaminska B. Inhibition of Akt kinase signalling and activation of Forkhead are indispensable for upregulation of FasL expression in apoptosis of glioma cells. Oncogene 2003;22:7617-27.
30. Grossman D, Altieri DC. Drug resistance in melanoma: mechanisms, apoptosis, and new potential therapeutic targets. Cancer Metastasis Rev 2001;20:3-11.
31. Rosenwirth B, Billich A, Datema R, Donatsch P, Hammerschmid F, Harrison R, Hiestand P, Jaksche H, Mayer P, Peichl P, Quesniaux V, Schatz F, et al. Inhibition of human immunodeficiency virus type 1 replication by SDZ NIM811, a nonimmunosuppressive cyclosporine analog. Antimicrob Agents Chemother 1994;38:1763-72.
32. Billich A, Hammerschmid F, Peichl P, Wenger R, Zenke G, Quesniaux V, Rosenwirth B. Mode of action of SDZ NIM 811, a nonimmunosuppressive cyclosporine A analog with activity against human immunodeficiency virus (HIV) type 1: interference with HIV protein-cyclophilin A interactions. J Virol 1995;69:2451-61.
33. Koo J. A randomized, double-blind study comparing the efficacy, safety and optimal dose of two formulations of cyclosporin, Neoral and Sandimmun, in patients with severe psoriasis. OLP302 Study Group. Br J Dermatol 1998;139:88-95.
34. Powles AV, Hardman CM, Porter WM, Cook T, Hulme B, Fry L. Renal function after 10 years' treatment with cyclosporine for psoriasis. Br J Dermatol 1998;138:443-9.
35. Berth-Jones J, Graham-Brown RA, Marks R, Camp RD, English JS, Freeman K, Holden CA, Rogers SC, Oliwiecki S, Friedmann PS, Lewis-Jones MS, Archer CB, et al. Long-term efficacy and safety of cyclosporine in severe adult atopic dermatitis. Br J Dermatol 1997;136:76-81.
36. Naeyaert JM, Lachapelle JM, Degreef H, de la Brassinne M, Heenen M, Lambert J. Cyclosporine in atopic dermatitis: review of the literature and outline of a Belgian consensus. Dermatology 1999;198: 145-52.
37. Al-Daraji WI, Grant KR, Ryan K, Saxton AR, Reynolds NJ. Localization of calcineurin/NFAT in human skin and psoriasis and inhibition of calcineurin/NFAT activation in human keratinocytes by cyclosporine A. J Invest Dermatol 2002;118:779-88.
38. Rothbard JB, Garlington S, Lin Q, Kirschberg T, Kreider E, McGrane PL, Wender PA, Khavari PA. Conjugation of arginine oligomers to cyclosporine A facilitates topical delivery and inhibition of inflammation. Nat Med 2000;6:1253-7.